Streetbeat News

Price Targets

CFB

Stephens & Co. analyst Matt Olney has reiterated an Equal-Weight rating on CrossFirst Bankshares (NASDAQ:CFB) and maintained a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 4:24 pm

IBTX

Stephens & Co. analyst Matt Olney has reiterated an Overweight rating on Independent Bank Gr (NASDAQ:IBTX) and maintained a price target of $61.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 4:21 pm

RBB

Stephens & Co. analyst Andrew Terrell has reiterated an Equal-Weight rating on RBB Bancorp (NASDAQ:RBB) and maintained a price target of $19.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 4:17 pm

ZION

Stephens & Co. analyst Terry McEvoy has maintained an Equal-Weight rating on Zions Bancorp (NASDAQ:ZION) and increased the price target from $46 to $48.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 4:14 pm

XOM

UBS analyst Jon Rigby has maintained a Buy rating on Exxon Mobil (NYSE:XOM) but has reduced the price target from $133 to $132.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 4:03 pm

PR

Six analysts have recently updated their ratings on Permian Resources (NYSE:PR), with a mix of bullish, somewhat bullish, and indifferent stances. The average 12-month price target is now $16.00, down from $17.00, with a high estimate of $18.00 and a low of $14.00. Analysts from RBC Capital, B of A Securities, UBS, Stifel, Wells Fargo, and Susquehanna have provided various ratings and price target adjustments. Permian Resources has shown a revenue growth rate of 37.97% as of September 30, 2023, but has below-average net margin, ROE, and ROA, with a conservative debt-to-equity ratio of 0.63.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 4:00 pm

DNA

Ginkgo Bioworks Holdings (NYSE:DNA) has received mixed reviews from financial analysts, with 2 bearish and 2 indifferent ratings in the past quarter. The average 12-month price target is $1.8, up from the previous $1.25, with a high estimate of $2.50 and a low of $1.10. Goldman Sachs analyst Matthew Sykes lowered the price target to $1.10 from $1.25, maintaining a 'Sell' rating, while Raymond James analyst Rahul Sarugaser announced a 'Market Perform' rating with a $2.50 target. Ginkgo Bioworks faces challenges with a -16.52% revenue decline, a net margin of -546.44%, and an ROE of -21.98%, but maintains a low debt-to-equity ratio of 0.32.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 4:00 pm

SEMR

SEMrush Hldgs (NYSE:SEMR) received mixed analyst ratings over the past three months, with 1 bullish and 3 indifferent ratings. The average 12-month price target is $12.75, up from $11.67, with a high of $15.00 and a low of $10.00. Analysts from Goldman Sachs, Piper Sandler, Needham, and Morgan Stanley have updated their ratings and price targets. SEMrush's financials show strong market capitalization, revenue growth, net margin, ROE, ROA, and a low debt-to-equity ratio, indicating solid financial health and market confidence.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 4:00 pm

ZION

RBC Capital analyst Jon Arfstrom has reiterated a 'Sector Perform' rating on Zions Bancorp (NASDAQ:ZION) and maintained a price target of $45.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 3:55 pm

UUUU

Roth MKM analyst Joe Reagor has maintained a Buy rating on Energy Fuels (AMEX:UUUU) and increased the price target from $9.25 to $10.5 as reported on January 22, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 3:55 pm